Peru - Sepanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - dexametasona, (21) fosfato sódica; dexametasona, acetato - suspensión inyectable - dexametasona, (21) fosfato sódica 320 mg;dexametasona, acetato 363 mg;excipientes c.s.p - antiinflamatorios: esteroidales sistémicos. - camelidos, caninos, caprinos, equinos, felinos, ovinos, porcinos, vacunos - está indicado cuando se requiera una acción corticosteroide rápida y a la vez duradera. también en casos de síndromes nutricionales, trastornos metabólicos, síndromes inflamatorios no infecciosos. asociado a antibioterapia en casos de osteoartritis, linfangitis, artritis, bronconeumonías, septicemias, mastitis e infecciones del tracto urogenital, entre otros.

Sepanyol - Sepanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ntc s.r.l. - dexametasona fosfato sodio - colirio en soluciÓn - 1 mg/ml - dexametasona fosfato sodio 1 mg - dexametasona

Peru - Sepanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

farmindustria s.a. - elixir - por ; dexametasona 10.000000 mg; - dexametasona

Chile - Sepanyol - ISPC (Instituto de Salud Pública de Chile)

laboratorio hospifarma chile ltda. - bacitracina; neomicina - bacitracina 1,250 g; neomicina sulfato 0,740 g - prevención y tratamiento de corto plazo de infecciones cutáneas en heridas leves causadas por gérmenes sensibles

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - inmunosupresores - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - inmunosupresores - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 y 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 y 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Peru - Sepanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - cefalexina, monohidrato; dexametasona, (21) fosfato sódica; gentamicina; vitamina a (retinol acetato) - suspensión intramamaria - cefalexina, monohidrato 200 mg;dexametasona, (21) fosfato sódica 0.75 mg;gentamicina 100 mg;vitamina a (retinol acetato) 10000 u.i.;excipientes c.s.p , cefalexina, monohidrato 200 mg; dexametasona, (21) fosfato sódica 0.75 mg; gentamicina 100 mg; vitamina a (retinol acetato) 10000 u.i.; excipientes c.s.p - antibacterianos (antibioticos): aminoglucosidos, b-lactamicos, antibióticos de uso especifico solo a asociados, asociación de grupos antibióticos. antiinflamatorios: esteroidales sistémicos. vitaminas: asociadas con medicamentos. - caprinos, ovinos, vacunos - indicado para el tratamiento de las mastitis en bovinos, ovinos y caprinos en producción láctea, causadas por gérmenes sensibles a la cefalexina y/o gentamicina. posee potente acción antiinflamatoria y está adicionado con vitamina a como regenerador epitelial de la glándula mamaria. el exclusivo sistema duo cap®, ofrece la posibilidad de realizar una aplicación profunda o una administración cercana al esfínter del pezón.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - mieloma múltiple - agentes antineoplásicos - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

mylan ireland limited - lenalidomida - mieloma múltiple - inmunosupresores - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - inmunosupresores - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) está indicado para el tratamiento de pacientes adultos no tratados previamente con mieloma múltiple que no son elegibles para el trasplante. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).